14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
MESO vs VCEL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Vericel Corporation (VCEL) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MESO carries a Unified Composite Score of 34.6/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin), whereas VCEL carries 35.6/100 (SELL) at $57.27 (60.5x Forward P/E, 8.3% operating margin).
Growth vs. Quality Trade-Off: VCEL earns the overall head-to-head edge with a stronger Unified Composite Score (35.6/100 SELL vs. MESO 34.6/100 SELL) and 0.30β · 74% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
Defensive Composite Rating Caution: Although VCEL compares more favorably head-to-head, both MESO (34.6/100 SELL) and VCEL (35.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: MESO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile VCEL trades in a Markup technical trend (SURGE options phase, RSI 75.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MESO vs VCEL. Trailing 12-month operating profitability (MESO -42.6% vs VCEL 8.3%) and valuation multiples (MESO N/M vs VCEL 60.5x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $2.9B market capitalization and 8.3% operating margin.
OpEx & R&D Reinvestment66.2% of Rev ($215M)
90D Engineering Disclosures0 Published
Investor FAQ MESO vs VCEL Key Questions & Quantitative Answers
As of Nov 16, 2026, Vericel Corporation (VCEL) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MESO carries a Unified Composite Score of 34.6/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin), whereas VCEL carries 35.6/100 (SELL) at $57.27 (60.5x Forward P/E, 8.3% operating margin). Growth vs. Quality Trade-Off: VCEL earns the overall head-to-head edge with a stronger Unified Composite Score (35.6/100 SELL vs. MESO 34.6/100 SELL) and 0.30β · 74% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although VCEL compares more favorably head-to-head, both MESO (34.6/100 SELL) and VCEL (35.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: MESO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile VCEL trades in a Markup technical trend (SURGE options phase, RSI 75.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VCEL leads the Growth & Scale pillar: MESO posts +390.7% YoY revenue growth and +0.0% YoY earnings growth on $120M TTM revenue (80.0% gross margin, -42.6% operating margin), compared with VCEL at +26.5% YoY revenue growth and +170.0% YoY earnings growth on $324M TTM revenue (74.5% gross margin, 8.3% operating margin). On trailing 12-month operating scale, MESO generates $120M in USD-normalized revenue versus $324M for VCEL. In operating R&D and SG&A reinvestment, MESO deploys N/A (0 90-day corporate R&D disclosures) versus 66.2% of Rev ($215M) (0 disclosures) for VCEL.
VCEL screens cheaper on headline valuation multiples. MESO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.1x EV/Revenue (-37.1% EBITDA margin), whereas VCEL trades at 60.5x Forward P/E, 90.3x Trailing P/E, N/M PEG, and 9.0x EV/Revenue (17.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MESO (-9.9% ROE) versus VCEL (9.4% ROE) capital efficiency.
In options market volatility and institutional positioning, MESO carries 76.8% implied volatility (37th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.18β · 78% Vol realized risk). By comparison, VCEL carries 44.1% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (0.30β · 74% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.